Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tissue plasminogen activator administration and nursing considerations.

A Greco

    Journal of Intravenous Nursing : the Official Publication of the Intravenous Nurses Society
    |January 1, 1989
    PubMed
    Summary

    Intravenous thrombolytic therapy, specifically tissue plasminogen activator (t-PA), is crucial for acute myocardial infarction (AMI) patients. Early treatment limits infarct size, improves heart function, and reduces mortality.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Optimizing Fixed-Duration Ven-I Regimen in CLL: Expert Insight and AI Comparison.

    Hematological oncology·2026
    Same author

    SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial.

    Cardio-oncology (London, England)·2025
    Same author

    Management of the ulnar nerve using an adipofascial flap in elbow surgery.

    Musculoskeletal surgery·2025
    Same author

    Anterior segment ischemia and ischemic optic neuropathy following encircling scleral buckling surgery and air tamponade.

    American journal of ophthalmology case reports·2025
    Same author

    Squamous cell carcinoma in rare case of Huriez Syndrome: The role of distant flaps.

    JPRAS open·2025
    Same author

    Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro.

    Journal of endocrinological investigation·2024

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Acute myocardial infarction (AMI) is increasingly treated with intravenous thrombolytic therapy.
    • Tissue plasminogen activator (t-PA) is a key thrombolytic agent.
    • Understanding t-PA benefits and risks is vital for effective patient care.

    Purpose of the Study:

    • To review the benefits and risks of intravenous thrombolytic therapy with t-PA in AMI patients.
    • To highlight the importance of limiting infarct size and salvaging myocardium.

    Main Methods:

    • Focus on tissue plasminogen activator (t-PA) as the primary thrombolytic agent.
    • Review of current data linking infarct size to mortality.
    • Emphasis on early reperfusion strategies.

    Main Results:

    Related Experiment Videos

    • Intracoronary thrombus is the primary cause of most AMIs.
    • Thrombolytic therapy dissolves thrombi, reestablishing coronary blood flow.
    • Early intervention with t-PA reduces infarct size, improves left ventricular function, and lowers mortality.

    Conclusions:

    • Intravenous thrombolytic therapy with t-PA is effective in managing AMI.
    • Early administration is associated with improved patient outcomes.
    • Nursing plays a critical role in successful thrombolytic therapy implementation.